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DantroleneAbstract A 33 year old lady with no obvious reason to suspect susceptibility to malignant hyper-
pyrexia (MH) succumbed to this unexpected complication in spite of attempts to save her life with
aggressive supportive measures. We are reporting this case of possible malignant hyperthermia
probably the seventh reported case in India and second from Kerala in the last decade (Saxena
and Dua, 2007; Punj et al., 2001; Gopalakrishnan et al., 2010; Jain, 2010; Ramakant and Singh,
2012; Sharma et al., 2012). This was the ﬁrst ever case of MH in our institution in 25 years This
emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with
appropriate lab controls and above all high index of suspicion and heightened awareness among
the anaesthesiologists of this potential albeit rare risk of MH in Indian population.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
A 33 year old lady with no obvious reason to suspect suscepti-
bility to malignant hyperpyrexia (MH) succumbed to this
unexpected complication in spite of attempts to save her life
with aggressive supportive measures. We are reporting this
case of possible malignant hyperthermia probably the seventh
reported [1–6] case in India and second from Kerala in the lastdecade. This was the ﬁrst ever case of MH in our institution in
25 years.
2. Case report
A thirty-three year old lady with breast cancer was scheduled
for modiﬁed radical mastectomy. She underwent ﬁbroade-
noma excision under local anaesthesia 12 years back. She
was known asthmatic on regular salbutamol inhaler and on
auscultation occasional rhonchi were present over the chest.
Her investigations were within normal limits. Pulmonary func-
tion test showed moderate obstruction. She was accepted for
anaesthesia under nebulised bronchodilator cover.
After hospitalisation she was optimised with nebulised
Duolin and Budecort. IV Deryphylline 200 mg and Hydrocor-
tisone 100 mg were given on the morning of surgery. She was
Table 1 Clinical indicators for calculating MH raw score.
Clinical indicator Points
Generalised muscle rigidity 15
PETCO2 >55 mmHg with appropriately
controlled ventilation
15
Arterial PaCO2 >65 mmHg 15
Inappropriate increase in temperature 106 C 10
Inappropriate sinus tachycardia 3
Ventricular tachycardia/Ventricular ﬁbrillation 3
Arterial base excess more negative than 8 mEq/L 10
Arterial pH <7.25 10
Total score 81 points.
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0.5 mg orally on the previous night and morning of surgery.
Her baseline vitals in the OT were pulse rate 82/min, blood
pressure 120/80 mmHg, and saturation 99% on room air. IV
Glycopyrrolate 0.2 mg, Midazolam 1 mg, Fentanyl 100 lg
were given. After preoxygenation anaesthesia was induced
with Ligncaine 60 mg, Propofol 100 mg and Vecuronium
6 mg, supraglottic airway Igel size 4 was inserted. Air entry
bilaterally was conﬁrmed and end tidal carbon dioxide was
normal. Thereafter controlled ventilation was provided with
33% oxygen in nitrous oxide and Isoﬂourane1% in circle sys-
tem and surgery started.
35 minutes after induction, fall in SpO2 to 96% and rise in
ETCO2 to 50 mmHg were noted. Pulse rate became 120/min
and blood pressure 140/96 mmHg. Since the patient was asth-
matic, bronchospasm was suspected, but chest auscultation
revealed good bilateral air entry. Light plane of anaesthesia
was suspected and additional doses of Propofol 50 mg and
Vecuronium 2 mg were given. Also fresh gas ﬂow increased
to 6 L, FiO2 increased to 0.5, changed to open circuit, and sat-
uration was restored to 100%.
In the next 10 min ETCO2 rose to 70 mmHg in spite of
slight manual hyperventilation with Bain’s circuit. Igel was
replaced with 7size oral endotracheal tube. Tachycardia 124/
min and blood pressure 140/96 mmHg persisted. Isoﬂourane
was cut off at this point. Surgeon was alerted to ﬁnish surgery
fast. Upper limb rigidity was noted at this time and surgeon
observed rigid pectoral muscle. Oral temperature recorded at
this time was 106 F. Provisionally diagnosis of malignant
hyperthermia was made at this time. Cooling measures were
immediately instituted. Cold saline infusion, cold compresses,
cold gastric lavage through Ryle’s tube and cold bladder wash
started. Rigidity of lower limbs noted at the time of catheteri-
sation and it was not possible to ﬂex the lower limbs. ABG was
done and report was combined metabolic and respiratory aci-
dosis [ph 6.5, PO2 115 mmHg, PCO2 176.5., HCO3 16.1 mmol/
L, BE -23, Na 148 mEq/L, K.5.6 mEq/L]. Thyroid function
test was done which was within normal limits.
Hyperventilation continued but ETCO2 kept on increasing
to 150 mmHg within 20 min, pulse rate 144/min and blood
pressure 160/96 mmHg. Additional doses of Propofol, Metolar
were given Hypermetabolic crisis due to thyroid storm was
ruled out since she never had thyroid problem and TFT was
normal. Aggressive cooling measures continued. Sodabicar-
bonate 100 mL given for acidosis correction. Surgery was ﬁn-
ished and we decided to electively ventilate the patient.
Relatives were informed of the patient’s critical condition.
Dantrolene was not available in our institution as efforts to
procure and stock it well in advance failed in spite of repeated
requests as the drug was not available in the Indian market.
Measures to outsource Dantrolene during the crisis had also
failed.
Patient then developed bradycardia with heart rate drop-
ping to 38/min not responding to Atropine (IV Atropine.
6 mg, 2 doses) and went into asystole. CPR started immedi-
ately, IV Adrenaline 1 mg two doses administered. ECG com-
plexes appeared with sinus tachycardia at a rate of 160/min
and peripheral pulses appeared, which worsened to stable ven-
tricular tachycardia with a rate of 180/min. Amiodarone
150 mg given slow IV , rate came down to 90/min. Dopamine
infusion started, but patient continued to have ventricular
tachycardia not responding to cardioversion at 100 J. She wentinto ventricular ﬁbrillation, deﬁbrillation, CPR and drugs
given as per 2010 AHA guidelines. There was no return of
spontaneous circulation, asystole ensued, resuscitation contin-
ued but patient could not be saved.
3. Discussion
The points clinching diagnosis of Malignant Hyperthermia in
our patient are [7],
1. Inappropriate rapid rise in end tidal CO2 to threefold of ini-
tial values despite maintaining hyperventilation [7].
2. Muscle rigidity not responding to additional doses of mus-
cle relaxant.
3. Inappropriate rise in body temperature to 106 F not
responding to cooling measures.
4. Combined respiratory and metabolic acidosis and BE -23 in
ABG.
5. Thyroid storm ruled out by normal TFT values [T3 92 ng/
dL, T4 8 lg/dL, TSH 3.4 mIU/mL].
6. Neurolept malignant syndrome ruled out as she was not on
any antipsychotic drugs.
7. No history suggestive of pheochromocytoma.
Larasch et al. [7] described a raw scoring for patients to pre-
dict the possibility that a suspected hypermetabolic crisis
occurring during anaesthesia is due to MH. Our patient had
a total score of 81 points (Table 1) which has a likelyhood
of almost certain MH.
We could not do any test regarding conﬁrmation of muscle
breakdown like blood CPK MB, serum myoglobin or urine
myoglobin due to rapid worsening and death of the patient.
The most conﬁrmatory test for MH, caffeine halothane con-
tracture testing [8] has to be done ideally after a period of
3 months of a hypermetabolic crisis to prevent false positive
results [9]. Currently we do not have facility for such testing
anywhere in India [10]. It is also necessary that the lab doing
a CHCT should have a control with which the contraction
has to be compared [11].
The relatives were explained of the situation and informed
of chances of MH susceptibility among other family members.
In the ﬁrst case report of MH in India [1] the author had
raised similar concerns of non availability of Dantrolene and
lab facilities for diagnosing MH. The editorial in Anaesthesiol-
ogy [13] focussed on Malignant Hyperthermia in India follow-
ing publishing a case report of MH in a boy from South India.
The author after reviewing three previous case reports of MH
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to MH in Indian population [14,15]. Further they identiﬁed
seven families of Indian origin who had MH reaction in the
UKMH registry.
The mortality of MH in western world is coming down due
to increased awareness among anaesthesiologists and Dantro-
lene [12]. We feel the urgent need of the hour is to be aware of
possibility of MH in Indian population and prompt institution
of treatment.
Dantrolene is a direct acting muscle relaxant available in
vials of 20 mg each. It has to be reconstituted in 60 mL of warm
water and given via blood set. It may cause hyperkalaemia and
cardiovascular collapse. Skeletal muscle weakness (22%) and
phlebitis (10%) are side effects. The usual dose is 2.5 mg/kg
13 A 70 kg person will require 175 mg which is almost
180 mg which is equal to 9 vials. Cost of each vial is Rs
12,500. Therefore minimum cost of treating a patient is Indian
Rupees 112,500. The cost of saving an MH patient if it occurs
once in a decade is close to Indian Rupees 12 lakhs considering
the fact that each year Dantrolene is stocked and wasted. But of
course human life cannot be equated with any amount of
money. It comes in a packing of 12 vials. The manufacturer is
UK based company. Minimum shipment is of 3 vials. Shelf life
is 12 months [15].
The reason why administrators are hesitant to import the
drug is because of cost, short shelf life, import hassles, and
possibility of wasting the drug and incurring loss to the hospi-
tal as the incidence of MH is rare. In India Dantrolene is
stocked in 2 corporate hospitals in New Delhi, Bangalore
and Chennai and 2 major government hospitals in Mumbai
and Kolkata and a major teaching hospital in Vellore. Techni-
cally it is difﬁcult to borrow this drug from hospitals which
have stocked it due to billing and licence issues.
Licence from the Drug Controller of India to import Dan-
trolene can be obtained for a particular patient or for an insti-
tution. These formalities take a few days to a fortnight.
The Indian Society of Anaesthesiologists should take initia-
tive to set up a national MH registry as there could be several
cases that are neither documented in journals nor notiﬁed any-
where. It is equally important to have lab facilities for con-
forming the diagnosis. The gold standard for diagnosing
MH, the caffeine halothane contracture testing [8] needs
proper laboratory standards relevant to the local population.
Genetic studies are taken up only in those who test positive
for contracture test. Currently a teaching institute in New
Delhi from where MH was ﬁrst reported is doing genetic test-
ing for MH.
There remains an ethical question. In spite of the rarity of
MH are we justiﬁed in providing anaesthetic services without
stocking Dantrolene to deal with that one case occurring once
in a decade knowing that MH is potentially lethal?Conﬂict of interest
There is no conﬂict of interest.
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